Data highlight both SER-603’s rational design that targets microbial functions linked to mucosal healing and gastrointestinal inflammation in IBD, as well as the advancement of microbiome-based ...
IBD, inflammatory bowel disease. SCFA, Short-Chain Fatty Acids; LPS, Lipopolysaccharide; IL-6, Interleukin-6; IL-8, Interleukin-8; IL-10, Interleukin-10; IL-12 ...
Research into GLP-1 medications and IBD is still at an early stage, and gastroenterologists aren't recommending that they be used outside their FDA-approved indications such as obesity and type 2 ...
Certain extraintestinal manifestations (EIMs) in inflammatory bowel disease (IBD) have distinct clinical, serologic, and genetic associations that reveal underlying mechanisms and indicate targets for ...
Despite an expanding therapeutic armamentarium, remission rates in inflammatory bowel disease (IBD) appear to plateau at 30–50% after 1 year of treatment, leading to the concept of a therapeutic ...
Inflammatory bowel disease (IBD) is a chronic condition that currently does not have a cure. However, certain lifestyle measures, such as keeping an IBD journal, can help you track symptoms, identify ...
Data highlight both SER-603’s rational design that targets microbial functions linked to mucosal healing and gastrointestinal inflammation in IBD, as well as the advancement of microbiome-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results